Three studies expand who finerenone can help in chronic kidney disease
Three landmark studies presented at the European Renal Association Congress in Glasgow found that finerenone slowed kidney decline and lowered the combined risk of kidney failure and serious heart problems by 23 percent in patients without diabetes. The results were published at
About half a billion people worldwide have chronic kidney disease not caused by diabetes. Three landmark studies, presented at the European Renal Association Congress in Glasgow and published simultaneously in The Lancet, NEJM and JAMA, found finerenone lowered the combined risk of kidney failure, disease progression, heart failure and cardiovascular death by 23 percent versus placebo in patients without diabetes. It also cut hospitalisation for heart failure or cardiovascular death by 20 percent and reduced all-cause death by 12 percent. High blood potassium occurred more often, but serious cases were low. Sources: The Lancet, NEJM, JAMA, European Renal Association Congress, UNSW, Medical Xpress, ScienceDaily.